Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA as Adjuvant Therapy After Radiotherapy and Hormone Therapy in High-Risk Prostate Cancer
2023-504912-13-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Sep 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Biochemical failure ratio. Planned start Sep 2023; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-504912-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504912-13-00.